Here are four updates from the past week to note:
RedHill Biopharma enrolled the last patient into its phase II study of Bekinda 12 mg. Researchers are conducting a randomized, double-blind, placebo-controlled phase II study evaluating Bekinda's safety and efficacy in 127 patients with irritable bowel syndrome with diarrhea.
RedHill Biopharma is hosting an analyst and investor R&D Day to discuss its drug Bekinda, a treatment for acute gastroenteritis and irritable bowel syndrome with diarrhea.
The endoscopy equipment market is likely to reach $35.3 billion by 2021, expanding at a 6.2 percent compound annual growth rate. Olympus Corp. and Boston Scientific Corp. are key vendors in the booming market.
The Society of American Gastrointestinal and Endoscopic Surgeons gave Mederi Therapeutics' Stretta Therapy for gastroesophageal reflux disease a strong recommendation in a new clinical spotlight review guideline statement.